<![CDATA[<h2>Jiangsu Hengrui Pharmaceuticals Co., Ltd.</h2>
<h3>Company Name:</h3><p>Jiangsu Hengrui Pharmaceuticals Co., Ltd.</p>
<h3>Tel:</h3><p>86-0518-85465745</p>
<h3>Fax:</h3><p></p>
<h3>Email:</h3><p></p>
<h3>Website:</h3><p>www.hengrui.com</p>
<h3>Country:</h3><p>China</p>
<h3>State:</h3><p></p>
<h3>City:</h3><p></p>
<h3>Zip/Postal Code:</h3><p></p>
<h3>Address:</h3><p>No. 7, Kunlun Mountain Road, Lianyungang Economic and Technological Development Zone, Jiangsu Province, China</p>
<h3>Main Product:</h3><p>Oncology Dryg, Cardiovascular & Metabolism Drug, Autoimmune Drug, Pain Drug, Anti-infection Drug</p>
<h3>Company Profile:</h3><p><p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a pharmaceutical company engaged in the development and commercialization of innovative and high-quality drugs. We are a well-known supplier of oncology drugs, surgical drugs, and interventional imaging solutions in China. Hengrui Pharma ranked 24th among the top 1,000 global pharma companies announced by the Torreya in 2021. We has been on the Pharma Exec’s annual listing of the top global pharmaceutical companies for the fourth consecutive year, rising from 47th in 2019 to 32nd in 2022.</p>
<p class="paddingtop40">Innovation is the core of Hengrui’s development strategy. Hengrui spent more than 900 million USD (6.2 billion RMB) in R&D in 2021, which is 23.95% of the 2021 revenue. We have built a large-scale, professional, and comprehensive innovative drug research staff of more than 5,400 people. Sixteen R&D centers were built around the world and several subsidiaries were established in the US, EU, Australia, and Japan. We have 11 innovative products marketed in china, more than 60 innovative candidates in the R&D stage and nearly 20 innovative products under clinical development around the world. By the end of 2021, 1806 patent applications have been submitted, with 360 patents granted in China and 478 patents granted worldwide, such as the US, EU, and Japan.</p>
<p class="paddingtop40">Internationalization is also an important development strategy of Hengrui. By the end of 2021, Hengrui’s products have entered more than 40 countries, and will continue to accelerate global market development, focusing on emerging markets. Hengrui has established manufacturing facilities all over the country and most of them conform with the USP, EUP, and JP standards. We have exported injections on a large scale to the US, EU, and Japan markets. Through our international partners, Hengrui has obtained more than 20 registration approvals including injections, oral preparations and inhalation anesthetics in the EU, US and Japan to benefit more patients around the world.</p>
<p class="paddingtop40">Hengrui will continue its engagement in the innovation and development of treatments for various diseases spanning oncology, metabolic diseases, autoimmune diseases, cardiovascular diseases, and other therapeutic areas to benefit patients globally.</p></p>
]]>